# Hepatitis A (HepA) CDC recommendations- tabular CDSS rules (optimal)

Updated on 2024-05-02

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Vaccine** | **#** | **Age1** | **Age2** | **SpecialCondition** | **Immunization record** | | | **MedIndication1** | **MedIndication2** | **MedIndication3** | **Todo1** | **Todo2** | **Todo3** | **Todo4** | **Note-display** | **Note** |
|  |  |  |  |  | **Y/N** | **Dose** | **Adm date** |  |  |  |  |  |  |  |  |  |
| **HepA** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Minimal age: 12 mon |
| **Regular and catch-up schedule** | | | | | | | | | | | | | | | | |
|  | 1 | >= 12 mon | <= 18 yrs |  | N |  |  |  |  |  | Admin 1st dose | Schedule the second dose >= 6 mon |  |  |  |  |
|  | 2 | <= 18 yrs |  |  | Y | 1 | >= 12 mon age |  |  |  | Admin 2nd dose if interval >= 6 mon |  |  |  |  |  |
|  | 3 | <= 18 yrs |  |  | Y | 1 | >= 12 mon age |  |  |  | Schedule 2nd dose make the interval >= 6 mon |  |  |  |  | Note: current date to 1st dose < 6 months |
| **International travel** | | | | | | | | | | | | | | | | |
|  | 4 | >= 6 mon | <= 11 mon | To countries with high or intermediate endemic hepatitis A |  |  |  |  |  |  | Admin 1st dose before departure | Schedule revaccination 1st dose >= 6 mon of first dose (12-23 mon of age) | Schedule revaccination 2nd dose >= 6 mon of revaccination 1st does (12-23 mon of age) |  |  |  |
|  | 5 | >= 12 mon |  | To countries with high or intermediate endemic hepatitis A | N |  |  |  |  |  | Admin 1st dose as soon as travel is considered |  |  |  |  |  |
| **HepA and HepB: Twinrix** | | | | | | | | | | | | | | | | |
|  | 6 | >= 18 yrs |  |  | N |  |  |  |  |  | Admin 1st dose | Schedule 2nd dose at 1 mon from 1st dose | Schedule 3rd dose at 6 mon from 1st dose |  |  |  |
|  | 7 | >= 18 yrs |  |  | N |  |  |  |  |  | Admin 1st dose | Schedule 2nd dose at 7 days from 1st dose | Schedule 3rd dose at 21 – 30 days from 1st dose | Schedule 4th dose at 12 mon from 1st dose |  |  |
|  | 8 |  |  |  |  |  |  | Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component, including neomycin and yeast |  |  | **Do not administer** |  |  |  |  | Contraindication |
|  | 9 |  |  |  |  |  |  | Moderate or severe acute illness with or without fever |  |  | Only admin if benefits outweigh risks for an adverse reaction |  |  |  |  | Precaution |
| **Contraindications and precautions** | | | | | | | | | | | | | | | | |
|  | 10 |  |  |  |  |  |  | Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component, including neomycin |  |  | **Do not administer** |  |  |  |  | Contraindication |
|  | 11 |  |  |  |  |  |  | Moderate or severe acute illness with or without fever |  |  | Only admin if benefits outweigh risks for an adverse reaction |  |  |  |  | Precaution |